Pharmacogenetics of osteoporosis: What is the evidence?

Current Osteoporosis Reports

Volumn 10, Issue 3, 2012, Pages 221-227

  Marini, Francesca ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiresorptive drugs; Gene polymorphisms; Individual drug response; Osteoporosis; Pharmacogenetic tests; Pharmacogenetics

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS RALOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETIDRONIC ACID; OSTEOPROTEGERIN; RALOXIFENE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; DISEASE PREDISPOSITION; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HORMONE SUBSTITUTION; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PHARMACOGENETICS; POSTMENOPAUSE OSTEOPOROSIS; VALIDATION STUDY; WNT SIGNALING PATHWAY;

BONE DENSITY CONSERVATION AGENTS; EPIGENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; OSTEOPOROSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84872190123     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-012-0110-7     Document Type: Article

References (46)

1. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358(22):2355-65.
2. Peacock M, Turner CH, Econs MJ, Foroud T. Genetics of osteoporosis. Endocr Rev. 2002;23:303-26.
3. Ralston SH, Uitterlinden AG. Genetics of osteoporosis. Endocr Rev. 2010;31:629-62.
4. Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008;371:1505-12.
5. Rivadeneira F, Styrkársdottir U, Estrada K, et al. Twenty bonemineral-density loci identified by large-scale meta-Analysis of genome-wide association studies. Nat Genet. 2009;41:1199-206.
6. Duncan EL, Danoy P, Kemp JP, et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet. 2011;7:e1001372.
7. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide metaanalysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genet. 2012;44:491-501.
8. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA. 2001;285:1415-8. (Pubitemid 32221875)
9. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-26.
10. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone. 2007;40:S5-8. (Pubitemid 46562594)
11. Nguyen TV, Eisman JA. Pharmacogenomics of osteoporosis: opportunities and challenges. J Musculoskelet Neuronal Interact. 2006;6:62-72.
12. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry. JAMA. 2000;283 (10):1318-21.
13. Johnson JA, Evans WE. Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. TrendsMol Med. 2002;8:300-5. (Pubitemid 34568386)
14. Yahata T, Quan J, Tamura N, et al. Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women. Hum Reprod. 2005;20:1860-6. (Pubitemid 40932369)
15. Rapuri PB, Gallagher JC, Knezetic JA, et al. Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas. 2006;53:371-9.
16. Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P, et al. Oestrogen-receptor-Alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol (Oxf). 2000;52:581-5. (Pubitemid 30337083)
17. Salmén T, Heikkinen AM, Mahonen A, et al. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women. J Bone Miner Res. 2000;15:2479-86.
18. Kurabayashi T, Tomita M, Matsushita H, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol. 1999;180:1115-20.
19. Kurabayashi T, Matsushita H, Tomita M, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effects of longterm hormone replacement therapy on bone mineral density. J Bone Miner Metab. 2004;22:241-7. (Pubitemid 38660955)
20. Giguère Y, Dodin S, Blanchet C, et al. The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J Bone Miner Res. 2000;15:1076-84.
21. Simsek M, Cetin Z, Bilgen T, et al. Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism. J Obstet Gynaecol Res. 2008;34:73-7. (Pubitemid 351143714)
22. Palomba S, Numis FG, Mossetti G, et al. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Reprod. 2003;18:192-8. (Pubitemid 36138876)
23. Heilberg IP, Hernandez E, Alonzo E, et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren Fail. 2005;27:155-61.
24. Marc J, Prezelj J, Komel R, et al. VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int. 1999;10:303-6. (Pubitemid 29476194)
25. Palomba S, Orio Jr F, Russo T, et al. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women, A 1-year multicenter, randomized and controlled trial. Osteoporos Int. 2005;16:943-52.
26. Qureshi AM, Herd RJ, Blake GM, et al. Colia1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int. 2002;70:158-63.
27. Arko B, Prezelj J, Komel R, et al. No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2002;81:147-52.
28. Kruk M, Ralston SH, Albagha OM. LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int. 2009;84:171-9.
29. Wang C, He JW, Qin YJ, et al. Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis. Honghua Yi Xue Za Zhi. 2009;89 (42):2958-62. Article in Chinese.
30. Kim H, Choe SA, Ku SY, et al. Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women. Menopause. 2011;18(7):808-13. The first osteoporosis pharmacogenetic study on genes of the Wnt signaling pathway.
31. Marini F, Falchetti A, Silvestri S, et al. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-Term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin. 2008;24:2609-15.
32. Olmos JM, Zarrabeitia MT, Hernández JL, et al. Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates. Pharmacogenomics J. 2010. doi:10.1038/tpj.2010.88.
33. Choi HJ, Choi JY, Cho SW, et al. Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J. 2010;51:231-8. A pharmacogenetic study about the role of genes of the mevalonate pathway in the response to NBPs.
34. Carbonell Sala S, Falchetti A, Martineti V, et al. Intron 1 polymorphism (A/C) of FDPS gene: a new genetic marker for N-BPs therapy response? [abstract SA121]. Presented at the ASBMR XXVII Annual Meeting, Nashville, USA, 2005. J Bone Miner Res. 2005;20(suppl1):s1-s512.
35. Haga H, Yamada R, Ohnishi Y, et al. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Singlenucleotide polymorphism. J Hum Genet. 2002;47:605-10.
36. Guañabens N, Peris P, Monegal A, et al. Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis. Calcif Tissue Int. 1994;54(5):431-4. (Pubitemid 24138764)
37. Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009;85(1):37-44.
38. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349-53.
39. Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-Term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-85.
40. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-Term complication of alendronate therapy? Injury. 2008;39(2):224-31.
41. Lenart BA, Neviaser AS, Lyman S, et al. Association of lowenergy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20(8):1353-62.
42. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346-50.
43. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294-301.
44. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42(5):841-7.
45. Sarasquete ME, García-Sanz R, Marín L, et al. Bisphosphonaterelated osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genomewide single nucleotide polymorphism analysis. Blood. 2008;112:2709-12.
46. Marini F, Tonelli P, Cavalli L, et al. Pharmacogenetics of bisphosphonate-Associated osteonecrosis of the jaw. Front Biosc (Elite Ed). 2010;3:364-70.